Ibio Inc (IBIO)
NASDAQ:IBIO
Want to see IBIO full AI Analyst Report?
IBIO Stock Chart & Stats
$2.06
-$0.02(-0.74%)
At close: 4:00 PM EST
$2.06
-$0.02(-0.74%)
Day’s Range― - ―
52-Week Range$0.56 - $3.82
Previous CloseN/A
Volume55.53K
Average Volume (3M)955.07K
Market Cap
$94.39M
Enterprise Value-$15.31M
Total Cash (Recent Filing)$74.80M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Sep 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding49,678,562
10 Day Avg. Volume749,657
30 Day Avg. Volume955,073
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-51.02
Enterprise Value/Gross Profit31.89
Enterprise Value/Ebitda0.68
Forecast
1Y Price Target
$5.50Price Target Upside166.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$180.00K
Bulls Say, Bears Say
Bulls Say
Clinical-stage TransitionAdvancing IBIO-600 into a first-in-human Phase 1 trial is a structural milestone: it formally transitions iBio into a clinical-stage company, enabling human safety/PD data generation, increasing the potential for milestone-driven partnerships or licensing and creating durable value inflection opportunities over coming quarters.
Experienced Board AdditionAdding a director with deep clinical development and biotech investment experience strengthens governance and strategic execution capability. Her background should help guide trial design, regulatory strategy and partner outreach—durable operational benefits during the transition to clinical development and commercialization planning.
Low Leverage And Equity BaseVery low financial leverage provides structural flexibility: limited interest burden and capacity to raise non-debt capital. A meaningful equity base supports balance sheet stability and provides a resource that management can use to fund development or secure partnering deals without immediate solvency pressure.
Bears Say
Minimal Revenue And Large LossesRevenue is negligible while operating losses are substantial and persistent, indicating operations are not commercially self-sustaining. Over the medium term this limits internal reinvestment capacity, forces reliance on external funding, and increases execution risk if capital markets tighten or partnerships do not materialize.
Sustained Cash BurnNegative operating and free cash flow at this scale is a persistent structural weakness. Continued burn necessitates frequent financing or partner-funded programs; dilution risk and funding uncertainty can limit long-term R&D planning, slow program timelines, or force prioritization of projects irrespective of strategic fit.
Equity Dilution And Balance Sheet VariabilityHistoric swings in equity indicate prior dilutive financings or volatile capitalization events. Structurally, reliance on equity raises to fund operations increases future dilution risk for shareholders and can complicate long-term planning, making sustained investor support a prerequisite for executing the clinical-development roadmap.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.56 and its highest was $3.82 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $94.39M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is Sep 29, 2026 which is in 118 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on May 12, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.007.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 49,678,562 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went down -3.727%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (166.99% Upside)
$5.50 (166.99% Upside)
Blogger Sentiment
Bullish
IBIO Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $97.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
145.45%
12-Months-Change
Fundamentals
Return on Equity
-53.86%
Trailing 12-Months
Asset Growth
349.32%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.50
▲(166.99% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
0.61% Insiders
2.62% Mutual Funds
22.49% Other Institutional Investors
72.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---